Table 2.

Cancer types for which the FDA-indicated antineoplastic-targeted agent is not correlated with the upregulated gene(s)

Cancer	Targeted protein: potential FDA-approved antineoplastic drug(s)
Nonbasal breast cancer	BRAF: sorafenib, CTLA4: ipilimumab, CYP19A1: letrozole, DHFR: methotrexate, DNMT1: azacitidine, EGFR: cetuximab, GSR: carmustine, HDAC (2, 4, 7, 11): vorinostat, TOP1: topotecan, TOP2A: doxorubicin, VEGF: bevacizumab
Breast invasive ductal cancer	DNMT1: azacitidine, HDAC1: vorinostat, PSMC4: bortezomib
Colorectal cancer	PDGFRB: pazopanib, RET: vandetanib
Chronic myeloid leukemia (3 groups)	ESR1: tamoxifen, RET: vandetanib, DNMT1: azacitidine, ERBB2: trastuzumab, HDAC3: vorinostat
CLL B-cell (3 groups)	CTLA4: ipilimumab, HDAC (1, 2, 6, 7, 9): vorinostat, PSMC (2, 3, 6): bortezomib, NQO1+: carmustine, CD52: alemtuzumab, MTOR: temsirolimus, PDGFRA: pazopanib, TOP1: topotecan
Follicular lymphoma	ABL1: imatinib, ESR2: tamoxifen, HDAC7: vorinostat
Multiple myeloma	ERBB2: trastuzumab, VEGF: bevacizumab
Myelodysplastic syndrome	HDAC2: vorinostat, PSMC2: bortezomib
Hepatocellular carcinoma	HDAC2: vorinostat
HBV hepatocellular carcinoma	MTOR: temsirolimus, PSMC5: bortezomib
HCV hepatocellular carcinoma (4 groups)	HDAC (1, 2, 4, 11): vorinostat, GSR: carmustine, DNMT1: azacitidine, TOP2A: doxorubicin, PSMC2: bortezomib
Pancreatic intraductal papillary-mucinous carcinoma (IPMN)	DHFR: methotrexate, GSR, NQO1: carmustine, HDAC1: vorinostat, TOP1: topotecan, TOP2A: doxorubicin
Invasive pancreatic cancer originating in the IPMN	TOP2A: doxorubicin, GSR*, NQO1: carmustine, DHFR: methotrexate
Chromophobe renal cell carcinoma	BRAF: sorafenib, DHFR: methotrexate, ESR1: tamoxifen, HDAC11: vorinostat, PSMC (2, 3, 6): bortezomib
Renal clear cell cancer	CD52: alemtuzumab
Renal papillary cell carcinoma	HDAC3: vorinostat, PSMC (1, 2, 3, 4): bortezomib

Note: numbers within parentheses are gene members.

Abbreviations: CLL, chronic lymphocytic leukemia; HBV, hepatitis B virus; HCV, hepatitis C virus.